Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
troxacitabine · 1 trial · 1 indication
Conventional Response Rate defined as the achievement of complete hematologic remission (CHR), partial hematologic remission (PHR), hematologic improvement (HI), partial response (PR), or back to chronic phase (BCP).
| Arm | Type | Description |
|---|---|---|
| troxacitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| troxacitabine | DRUG | - |
DISEASE CHARACTERISTICS: Diagnosis of Philadelphia chromosome-positive blastic phase chronic myelogenous leukemia (CML) with blasts of non-lymphoid origin Blastic phase defined as: At least 30% blasts in the blood or bone marrow OR Presence of extramedullary infiltration outside the liver or spleen ...
Top 20 of 63 competitors
Troxacitabine is an investigational small molecule being studied for the treatment of leukemia, specifically chronic myelogenous leukemia. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
Troxacitabine is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with leukemia.
Troxacitabine is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. A Phase 2 trial has been completed to assess its effects in patients with chronic myelogenous leukemia.
Troxacitabine has one completed clinical trial, NCT00012259, titled 'Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia.' This Phase 2 study enrolled 31 participants in the United States and Canada and was not randomized, double-blinded, or controlled.
No alternative names for troxacitabine have been reported. It is identified solely by its generic name in clinical trial records and development documentation.